Avalon Global Asset Management’s Edwards Lifesciences EW Stock Holding History

Avalon Global Asset Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-65,000	Closed	-$5.05M	–	46
2025 Q3	$5.05M	Buy	65,000 +10,000	+18%	+$781K	0.58%	38
2025 Q2	$4.3M	Buy	+55,000	New	+$4.1M	0.51%	41
2018 Q1	–	Sell	-60,000	Closed	-$2.25M	–	60
2017 Q4	$2.25M	Buy	+60,000	New	+$2.2M	1.12%	39
2017 Q1	–	Sell	-60,000	Closed	-$1.87M	–	43
2016 Q4	$1.87M	Buy	+60,000	New	+$1.94M	1.54%	28

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Avalon Global Asset Management's EW Position: Q4 2025 in Review

Avalon Global Asset Management sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 65,000 shares — an estimated $5.05M sold.

Avalon Global Asset Management first reported a position in EW in Q4 2016 and held it in 4 quarters. The position peaked at $5.05M in Q3 2025. 1,313 funds tracked by Wall St. Rank hold EW as of Q4 2025.

Avalon Global Asset Management reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
Avalon Global Asset Management sold 65,000 Edwards Lifesciences shares in Q4 2025, an estimated $5.05M.
Avalon Global Asset Management first reported a position in Edwards Lifesciences in Q4 2016 and held it in 4 quarters.
Avalon Global Asset Management's Edwards Lifesciences position peaked at $5.05M in Q3 2025.
1,313 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on Avalon Global Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.